FDC
531599Business Responsibility and Sustainability Reporting (BRSR)
BRSR for FY 2025-26
FDC Ltd is a prominent Indian pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceutical formulations, APIs, and nutraceutical products. Established in 1936 and headquartered in Mumbai, FDC has a robust manufacturing infrastructure, with facilities that are compliant with international regulatory standards including US FDA, UK MHRA, and WHO-GMP. Its product portfolio spans therapeutic segments such as oral rehydration salts, anti-infectives, gastroenterology, ophthalmology, and dermatology.
Business Responsibility and Sustainability Reporting (BRSR)
BRSR for FY 2025-26
Intimation Of Book Closure And Cut-Off Date In Accordance With Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirement) 2015
This is to inform you that the register of members and share transfer books of the Company will remain closed from Thursday, September 17, 2026, to Wednesday, September 23, 2026 (both days inclusive) for the 86th AGM of the Company. The cut-off date shall be Wednesday, September 16, 2026
Reg. 34 (1) Annual Report.
Annual Report for FY 2025-26
Notice Of 86Th Annual General Meeting For The FY 2025-26
Please find enclosed Notice of 86th Annual General meeting for the FY 2025-26
Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find attached copies of the newspaper advertisement in respect of the 86th AGM of the Company
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Announcement under Regulation 30
Grant Of Marketing Authorisation From MHRA, UK For Atropine 1.0% W/V Eye Drops, Solution.
This is to inform you that the company''s Subsidiary, FDC International Ltd., has received Marketing Authorisation from the MHRA, UK, for Atropine 1.0% w/v Eye Drops, Solution.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release Q1 FY 2026-27 Results.
Financial Results For The Quarter Ended June 30, 2026
Financial Results for the quarter ended June 30, 2026
Board Meeting Outcome for Board Meeting Outcome For Outcome For The Board Meeting Held On August 05, 2026.
Outcome for the Board Meeting Held on 5th August, 2026.
FDC Ltd
About
FDC Ltd is a prominent Indian pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceutical formulations, APIs, and nutraceutical products. Established in 1936 and headquartered in Mumbai, FDC has a robust manufacturing infrastructure, with facilities that are compliant with international regulatory standards including US FDA, UK MHRA, and WHO-GMP. Its product portfolio spans therapeutic segments such as oral rehydration salts, anti-infectives, gastroenterology, ophthalmology, and dermatology.
The company operates both domestically and globally, exporting to over 50 countries across regulated and emerging markets.
FDC Ltd is known for its leadership in oral rehydration salts (ORS) in India and maintains a strong position in several branded generics categories. The company emphasizes research and development, with in-house capabilities supporting continuous product innovation. FDC is committed to sustainability and compliance, focusing on backward integration, quality assurance, and operational efficiency.
Business Model & Strategy
FDC Ltd generates revenue primarily through the manufacturing and sale of pharmaceutical formulations, bulk drugs (APIs), and nutraceutical products. Its business model emphasizes branded generics, exports, and contract manufacturing. The company leverages its broad domestic distribution network and established brands like Electral (ORS) to maintain leadership positions in key segments while expanding its presence in chronic therapeutic areas through new product launches.
Growth strategies include diversifying the product mix, investment in R&D for differentiated formulations, and entering new geographies through regulatory filings and partnerships. FDC also invests in process innovation and modernization of plants to increase cost competitiveness and compliance with global regulatory requirements.
Management Overview
12 MembersMr.Uday Kumar Gurkar
Non-Executive - Independent Director-ChairpersonMr.Mohan Anand Chandavarkar
Executive Director-MDMr.Nandan Mohan Chandavarkar
Executive DirectorMr.Ashok Anand Chandavarkar
Executive DirectorMr.Ameya Ashok Chandavarkar
Executive DirectorMs.Nomita Ramdas Chandavarkar
Non-Executive - Non Independent DirectorMr.Mahesh Chandru Bijlani
Non-Executive - Independent DirectorMr.Vijay Suresh Maniar
Non-Executive - Independent DirectorMr.Vijay Nautamlal Bhatt
Non-Executive - Independent DirectorMs.Charuta Nityanath Mandke
Non-Executive - Independent DirectorMr.Vijay Bhatt
Chief Financial OfficerVarsharaniKatre
Company Secretary & Compliance OfficerAwards & Recognition
4 Awards- Electral (ORS) brand recognized as one of the most trusted healthcare brands in India (2024)
- Recipient of the Golden Peacock Award for Quality (2023)
- Included in the 'Best Companies to Work For – Pharmaceuticals' by several trade and industry bodies (2024)
- Member of UN Global Compact Network India, reflecting ESG commitment (2024)
Market Information
Company Timeline
88+ Years of Excellence | 8 Major Milestones
Founded as Fairdeal Corporation Private Limited.
Forayed into pharmaceutical manufacturing.
Launched Electral, India's leading ORS brand.
Converted to a public limited company.
Listed on BSE and NSE following IPO.
Received US FDA and UK MHRA approvals for key manufacturing sites.
Launched next-gen formulations in ophthalmology and dermatology.
Expanded exports to regulated European and Latin American markets; enhanced ESG disclosures and sustainability initiatives.
The Next Evolution
Contact Information
Registered Office
B-8, MIDC Industrial Area, Dist Aurangabad
Tel: 0240-2554407 / 2554967 / 2554299,
Fax: 0240-2554299,
Email: investors@fdcindia.com; waluj@fdcindia.com
Website: fdcindia.com
Corporate Actions
11| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Interim Dividend ₹5 per share | 11 Feb 2026 Wednesday | 11 Feb 2026 Wednesday | - | - |
Interim Dividend ₹5 per share | 22 Nov 2024 Friday | 22 Nov 2024 Friday | - | - |
Buy Back of Shares | 25 Aug 2023 Friday | 25 Aug 2023 Friday | - | - |
Buy Back of Shares | 17 Feb 2022 Thursday | 19 Feb 2022 Saturday | - | - |
Buy Back of Shares | 20 Aug 2020 Thursday | 21 Aug 2020 Friday | - | - |
Interim Dividend ₹0.80 per share | 19 Mar 2020 Thursday | 21 Mar 2020 Saturday | - | - |
Buy Back of Shares | 06 Jun 2019 Thursday | 07 Jun 2019 Friday | - | - |
Buy Back of Shares | 26 Feb 2018 Monday | 27 Feb 2018 Tuesday | - | - |
Dividend ₹2.25 per share | 08 Aug 2017 Tuesday | - | 10 Aug 2017 Thursday | 19 Aug 2017 Saturday |
Interim Dividend ₹2.25 per share | 17 Mar 2016 Thursday | 19 Mar 2016 Saturday | - | - |
Final Dividend ₹2.25 per share | 23 Sep 2015 Wednesday | - | 26 Sep 2015 Saturday | 30 Sep 2015 Wednesday |
₹5,422 Cr.
₹339
₹528 / 313
14.77
₹152.64
2.19
₹22.58
₹1.00
1.5 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 1,134 | 1,413 | 1,430 | 1,604 | 1,834 | 2,045 | 2,199 | 2,284 | 2,329 |
| Expenses | - | - | - | 893 | 1,092 | 1,040 | 1,315 | 1,576 | 1,648 | 1,842 | 1,889 | 1,919 |
| Profit | - | - | - | 174 | 240 | 301 | 216 | 194 | 305 | 267 | 281 | 293 |
| Tax | - | - | - | 67 | 80 | 87 | 73 | 64 | 91 | 90 | 93 | 97 |
| EPS | - | - | - | 10 | 14 | 18 | 13 | 12 | 19 | 16 | 17 | 8.14 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 1,640 | 1,813 | 1,956 | 2,270 | 2,343 | 2,468 | 2,714 | 2,919 | - |
| Equity And Liabilities | - | - | - | 1,640 | 1,813 | 1,956 | 2,270 | 2,343 | 2,468 | 2,714 | 2,919 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 03 May '19 | Mar 2020 21 Apr '20 | Mar 2021 04 May '21 | Mar 2022 20 Apr '22 | Mar 2023 13 Apr '23 | Mar 2024 18 Apr '24 | Mar 2025 17 Apr '25 | Mar 2026 14 Apr '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | - | - | - | - | - |
| Promoter And Promoter Group | - | - | - | 69.07% | 69.24% | 69.35% | 69.36% | 69.50% | 69.66% | 69.66% | 69.66% | - |
| Non Institutions | - | - | - | 16.82% | 19.50% | 20.92% | 20.27% | 18.43% | 20.76% | 21.42% | 21.65% | - |
| FII | - | - | - | - | - | - | - | 3.80% | 2.65% | 2.55% | 2.40% | - |
| DII | - | - | - | - | - | - | - | 8.27% | 6.94% | 6.37% | 6.29% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
FDC Ltd
FDC Ltd
FDC Ltd is a prominent Indian pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceutical formulations, APIs, and nutraceutical products. Established in 1936 and headquartered in Mumbai, FDC has a robust manufacturing infrastructure, with facilities that are compliant with international regulatory standards including US FDA, UK MHRA, and WHO-GMP. Its product portfolio spans therapeutic segments such as oral rehydration salts, anti-infectives, gastroenterology, ophthalmology, and dermatology.
The company operates both domestically and globally, exporting to over 50 countries across regulated and emerging markets.
FDC Ltd is known for its leadership in oral rehydration salts (ORS) in India and maintains a strong position in several branded generics categories. The company emphasizes research and development, with in-house capabilities supporting continuous product innovation. FDC is committed to sustainability and compliance, focusing on backward integration, quality assurance, and operational efficiency.
FDC Ltd generates revenue primarily through the manufacturing and sale of pharmaceutical formulations, bulk drugs (APIs), and nutraceutical products. Its business model emphasizes branded generics, exports, and contract manufacturing. The company leverages its broad domestic distribution network and established brands like Electral (ORS) to maintain leadership positions in key segments while expanding its presence in chronic therapeutic areas through new product launches.
Growth strategies include diversifying the product mix, investment in R&D for differentiated formulations, and entering new geographies through regulatory filings and partnerships. FDC also invests in process innovation and modernization of plants to increase cost competitiveness and compliance with global regulatory requirements.
Electral (ORS) brand recognized as one of the most trusted healthcare brands in India (2024)
Recipient of the Golden Peacock Award for Quality (2023)
Included in the 'Best Companies to Work For – Pharmaceuticals' by several trade and industry bodies (2024)
Member of UN Global Compact Network India, reflecting ESG commitment (2024)
Founded as Fairdeal Corporation Private Limited.
Forayed into pharmaceutical manufacturing.
Launched Electral, India's leading ORS brand.
Converted to a public limited company.
Listed on BSE and NSE following IPO.
Received US FDA and UK MHRA approvals for key manufacturing sites.
Launched next-gen formulations in ophthalmology and dermatology.
Expanded exports to regulated European and Latin American markets; enhanced ESG disclosures and sustainability initiatives.
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon